. | Pol13 . | Pol14 . | Pol17 . | Pol19 . |
---|---|---|---|---|
Sex | F | F | F | M |
Mutation | R201H | R201H | K170N | R201H |
Birth weight (g) | Unknown | 2,600 | 2,200 | 3,200 |
Age diabetes diagnosed (months) | 2 | 3 | 2 | 3 |
Age at examination (years) | 34 | 20 | 22 | 50 |
Height (cm) | 150 | 160 | 168 | 168 |
Weight (kg) | ||||
At study entry | 51.1 | 58.0 | 51.8 | 62.2 |
At follow-up | 44.2 | 45.1 | 48.1 | NA |
BMI (kg/m2) | ||||
At study entry | 22.7 | 22.7 | 18.4 | 22.0 |
At follow-up | 19.6 | 17.6 | 17.0 | NA |
Daily insulin dose at study entry (units) | 58 | 40–45 | 55 | 23 |
Sulphonylurea used | Glipizide gastrointestinal therapeutic system | Glipizide gastrointestinal therapeutic system | Glibenclamide | Glipizide gastrointestinal therapeutic system |
Initial sulphonylurea dose (mg) | 50 | 50 | 60 | 45 |
Sulphonylurea dose at follow-up (mg) | 40 | 30 | 50 | NA |
Serum creatinine level at study entry (μmol/l) | 68.4 | 58.5 | 64.6 | 84.8 |
A1C (%) | ||||
At study entry | 7.2 | 8.7 | 10.2 | 9.7 |
At the end of follow-up | 5.9 | 5.3 | 7.8 | NA |
Serum fasting C-peptide level (ng/ml) | ||||
At study entry | 0.18 | 0.10 | <0.05 | <0.05 |
After transfer | 1.88 | 1.06 | 1.71 | NA |
Insulin sensitivity (mg · kg−1 · min−1) | ||||
M at study entry | 3.91 | 2.76 | 6.66 | 4.64 |
M at follow-up | 13.40 | 7.06 | 10.50 | NA |
Total cholesterol level (mmol/l) | ||||
At study entry | 3.1 | 4.3 | 6.7 | 4.8 |
After transfer | 3.2 | 2.9 | 5.0 | NA |
Triglyceride level (mmol/l) | ||||
At study entry | 0.75 | 0.74 | 1.27 | 1.40 |
After transfer | 0.79 | 0.75 | 1.51 | NA |
Retinopathy | ||||
At study entry | Proliferative DR; prior multiple laser coagulations | Nonproliferative DR | Nonproliferative DR | No DR |
At follow-up | Progression; required additional lasers | Regression | Regression | NA |
Albumin/creatinine ratio (mg/mmol) | ||||
At study entry | 11.4 | 0.5 | 0.4 | Not examined |
At follow-up | 2.8 | 0.8 | 1.0 | NA |
. | Pol13 . | Pol14 . | Pol17 . | Pol19 . |
---|---|---|---|---|
Sex | F | F | F | M |
Mutation | R201H | R201H | K170N | R201H |
Birth weight (g) | Unknown | 2,600 | 2,200 | 3,200 |
Age diabetes diagnosed (months) | 2 | 3 | 2 | 3 |
Age at examination (years) | 34 | 20 | 22 | 50 |
Height (cm) | 150 | 160 | 168 | 168 |
Weight (kg) | ||||
At study entry | 51.1 | 58.0 | 51.8 | 62.2 |
At follow-up | 44.2 | 45.1 | 48.1 | NA |
BMI (kg/m2) | ||||
At study entry | 22.7 | 22.7 | 18.4 | 22.0 |
At follow-up | 19.6 | 17.6 | 17.0 | NA |
Daily insulin dose at study entry (units) | 58 | 40–45 | 55 | 23 |
Sulphonylurea used | Glipizide gastrointestinal therapeutic system | Glipizide gastrointestinal therapeutic system | Glibenclamide | Glipizide gastrointestinal therapeutic system |
Initial sulphonylurea dose (mg) | 50 | 50 | 60 | 45 |
Sulphonylurea dose at follow-up (mg) | 40 | 30 | 50 | NA |
Serum creatinine level at study entry (μmol/l) | 68.4 | 58.5 | 64.6 | 84.8 |
A1C (%) | ||||
At study entry | 7.2 | 8.7 | 10.2 | 9.7 |
At the end of follow-up | 5.9 | 5.3 | 7.8 | NA |
Serum fasting C-peptide level (ng/ml) | ||||
At study entry | 0.18 | 0.10 | <0.05 | <0.05 |
After transfer | 1.88 | 1.06 | 1.71 | NA |
Insulin sensitivity (mg · kg−1 · min−1) | ||||
M at study entry | 3.91 | 2.76 | 6.66 | 4.64 |
M at follow-up | 13.40 | 7.06 | 10.50 | NA |
Total cholesterol level (mmol/l) | ||||
At study entry | 3.1 | 4.3 | 6.7 | 4.8 |
After transfer | 3.2 | 2.9 | 5.0 | NA |
Triglyceride level (mmol/l) | ||||
At study entry | 0.75 | 0.74 | 1.27 | 1.40 |
After transfer | 0.79 | 0.75 | 1.51 | NA |
Retinopathy | ||||
At study entry | Proliferative DR; prior multiple laser coagulations | Nonproliferative DR | Nonproliferative DR | No DR |
At follow-up | Progression; required additional lasers | Regression | Regression | NA |
Albumin/creatinine ratio (mg/mmol) | ||||
At study entry | 11.4 | 0.5 | 0.4 | Not examined |
At follow-up | 2.8 | 0.8 | 1.0 | NA |
DR, diabetic retinopathy; NA, not applicable.